Feb 17, 2026 05:31PM

Jan 30, 2026 01:55PM

Oct 9, 2025 06:57AM

Oct 1, 2025 01:20PM

Aug 4, 2025 05:53AM

Apr 10, 2025 05:32AM

Jan 14, 2025 04:59AM Goldman Sachs Reiterates Buy Rating on Regeneron Pharma (REGN)

Jan 13, 2025 11:15AM

Jan 13, 2025 07:41AM

Jan 13, 2025 06:30AM

Dec 16, 2024 07:03AM

Dec 11, 2024 09:44AM

Sep 24, 2024 02:18PM

Jun 3, 2024 12:28PM BMO Capital Reiterates Outperform Rating on Regeneron Pharma (REGN)

Aug 5, 2021 06:05PM

Jan 12, 2021 06:52AM

May 8, 2019 08:00AM

Sep 12, 2018 08:00AM

Sep 12, 2018 06:28AM

Sep 12, 2018 01:01AM

Sep 12, 2018 01:00AM FDA to review supplemental Biologics License Application for Praluent® (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events

Sep 12, 2018 12:59AM

Mar 2, 2018 05:49AM

Mar 2, 2018 01:01AM

Mar 2, 2018 01:00AM

Mar 2, 2018 01:00AM

Dec 11, 2017 07:04AM

Dec 11, 2017 07:00AM Regeneron Announces FDA Acceptance of sBLA Filing for 12-Week Dosing of EYLEA® (aflibercept) Injection for Patients with Wet AMD

Jun 26, 2017 09:29AM

Apr 28, 2017 05:45AM

Apr 28, 2017 01:00AM

Mar 28, 2017 12:43PM

Feb 13, 2017 06:59AM

Feb 10, 2017 05:36AM

Feb 9, 2017 06:30AM Regeneron Reports Fourth Quarter and Full Year 2016 Financial and Operating Results

Feb 6, 2017 02:27AM

Jan 10, 2017 08:55AM

Jan 6, 2017 09:29AM

Jan 5, 2017 06:06PM

Dec 8, 2016 06:21AM

Dec 8, 2016 01:00AM

Dec 8, 2016 01:00AM Regeneron and Sanofi Announce Marketing Authorization Application for Dupixent® (dupilumab) Accepted for Review by the EMA

Oct 3, 2016 11:20AM

Oct 3, 2016 09:30AM

Oct 3, 2016 06:32AM

Oct 1, 2016 02:00AM

Sep 26, 2016 11:16AM

Sep 26, 2016 06:18AM

Sep 26, 2016 01:00AM Sanofi and Regeneron Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA

Sep 26, 2016 01:00AM

14,982 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All